Trial Profile
A Phase Ib, Single- and Multiple-Dose, Open-Label Study of The Safety, Pharmacokinetics and Pharmacodynamics of Obinutuzumab in Adults With End-Stage Renal Disease and Hypersensitization Awaiting Renal Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2020
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Immune globulin
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lupus nephritis; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 01 Jul 2019 Results assessing safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, published in the American Journal of Transplantation.
- 02 Jan 2019 Status changed from active, no longer recruiting to completed.
- 29 Oct 2018 Planned End Date changed from 5 Dec 2018 to 27 Nov 2018.